"The MRI demonstrates a progressive loss of cerebral volume" is typically a descriptor of senescence or in the case of multiple sclerosis (MS), a descriptor of advanced, progressive disease in older MS patients. It is not what most would expect in an MRI report of a child. In this issue, Bartels et al. demonstrate that brain volume is already reduced in children imaged at the time of a first MS attack. 1 The authors compared total and regional brain volumes of 37 children with acute demyelination of the central nervous system, all of whom met 2017 McDonald criteria for MS 2 at onset or on the basis of a second clinical attack or accrual of new MRI lesions, to the normative brain volumes provided by the National Institutes of Health (NIH) Pediatric MRI repository. Scans were obtained prior to administration of corticosteroids, avoiding any potential confounding of acute exposure to corticosteroids on brain volume ("pseudoatrophy"). Relative to age-matched values, whole brain volume as well as the volume of gray and white matter, were reduced. For the 21 MS patients re-imaged 2 years later, z-scores were further reduced for whole brain and white matter volumes, with a corresponding increase in intraventricular cerebrospinal fluid volume. Lesion volumes, notably infratentorial lesions, correlated with reduced brain volumes. The volume of cerebrospinal fluid (CSF) correlated with lesion volume and, on serial analyses, with relapse rate over the 2-year study period. At the second timepoint, patients with an Expanded Disability Status Scale (EDSS) score 3 greater than 1 had lower whole brain volumes.
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The study is limited by sample size, as is true of most studies of pediatric-onset MS owing to the relative rarity of MS onset in this age group. MRI scans were obtained from seven sites, and while analyzed centrally, scanners were not equilibrated using structural phantoms. The three-dimensional (3D) MPRAGE sequence used for volumetric analysis was, however, matched to the same sequence utilized for the NIH normative data set. Of the 21 imaged twice, 62% received one or more MS disease-modifying therapy in the 2-year period from onset to 2 years, and thus potential treatment effects are potential confounds. Despite these limitations, the key findings of reduced brain volume at onset and failure of age-expected brain growth remain robust.
While the clinical onset of MS is defined by the sentinel clinical attack, the biological onset of the disease predates clinical disease expression. Evidence supporting this contention includes baseline imaging demonstrating focal areas of permanent tissue loss, socalled "black holes," and a high volume of T2 bright clinically silent lesions with variable enhancementsuggestive of differential lesion age. The present study, and those discussed below, arguably provide the most compelling evidence of a subclinical phase.
Findings of Bartel et al, mirror several prior observations. In a cross-sectional study of a prospectively recruited pediatric cohort, whole brain and regional volumes of brain scans were obtained within 3 months of a first attack in 38 pediatric MS patients, all imaged on the same scanner, as well scans from the same NIH data set as used by Bartels et al, and from 33 healthy controls (to exclude any scanner-specific effects). 4 The cohort is very similar to that of Bartels et al., with a mean age in both studies averaging 15 years at first attack. Normalized brain volumes were reduced (-1.09 SD ± 1.49, p = 0.0002) to a similar magnitude of that found by Bartels et al. Thalamic volumes were further reduced (after correction for brain volume) by an addition 0.68 SD (±1.72, p = 0.02). Unique to this study was the finding of reduced intracranial volumes, implicating reduction in head size. Given that the majority of head growth occurs in early childhood, this findings raises the possibility of a sufficiently long period of subclinical MS disease activity to negatively impact fundamental brain growth even prior to clinical onset.
The second study from this prospective Canadian cohort, analyzed 185 research protocol scans from 36
Are children with multiple sclerosis really "old" adults MS patients (2-11 scans per patient), 50 serial scans from 25 healthy youth (imaged twice), and 874 scans from 339 healthy children enrolled in the NIH MRI repository. 5 Unlike the methods employed by Bartels et al. (2-point z-scores), Aubert-Broche et al. utilized voxel-based morphometry and mixed effect modeling to define volume trajectories. The four key findings of this study included reduced brain volumes at onset, failure to achieve the age-expected rate of brain growth, marked reduction in maximal brain volume (which peaks in mid-adolescence), and atrophy commencing at approximately age 15 years. Thalamic volumes, the brain region most negatively impacted in the MS group, declined continuously, with no appreciable growth irrespective of age at onset. In a separate analysis of the same cohort, Weier et al. 6 also demonstrated reduced cerebellar volumes at onset, failure of normal cerebellar growth, and subsequent and progressive loss of cerebellar volumes. In all three of these Canadian cohort studies, volumetric data correlated only moderately with T2 lesion volumes, and did not associate with physical disability (with EDSS scores remaining very low over time). The association of reduced brain volume and higher EDSS (dichotomized as zero vs 1 or higher) in the paper by Bartels et al., while statistically significant, is of limited clinical significance given the very low EDSS scores in their cohort as well, consistent with studies of pediatric MS patients who rarely demonstrate physical disability early in their disease course.
Yeh et al. performed an interesting cross-sectional study of four groups: 17 pediatric MS patients matched for disease duration with 81 adult-onset MS patients (mean time at scan from onset 2.7 years, ±2.6), and 33 pediatric-onset now adult MS patients and 300 adult-onset MS patients matched for disease duration (mean disease duration 20 years, ±10.9). Using the brain parenchymal fraction, no differences were found between groups. Such analysis, while very interesting from a comparative perspective, does not account for age-expected brain volumes and thus may have failed to appreciate the loss of volume. What this study does support, however, is that pediatric-onset disease does not spare patients from T2 and T1 lesion accrual, as these volumes were very similar between pediatric and adult MS patients at similar time points from disease onset.
Highly effective therapies offer optimism for improved clinical outcomes for children and adults living with MS. The recent PARADIGMS trial, the first completed Phase III clinical trial in pediatric MS, demonstrated superiority of fingolimod as compared to interferon beta 1a by intramuscular injection over 2 years. 7 An important finding in this study was the mitigation of the annualized rate of brain atrophy in the fingolimod arm (-0.48%, -0.65 to −0.3) versus interferon (-0.80%, -0.98 to −0.61). While encouraging, it is noteworthy that even in the fingolimod treated patients, who experienced an 82% relative reduction in clinical relapse rate, brain atrophy continued. It remains to be determined whether longer periods of treatment, with sustained clinical disease control, will slow brain atrophy.
While the chronicity of MS is postulated to drive the progressive loss of brain volume in both pediatric and adult MS patients, even monophasic demyelination can lead to progressive brain atrophy over time. 8 Serial research brain MRI scans, obtained from 18 children with acute disseminated encephalomyelitis (ADEM) and 65 children with monophasic demyelination (optic neuritis, transverse myelitis, other) demonstrated reduced age-expected brain growth, most notable in the white matter, relative to the NIH normative cohort. Despite the monophasic nature of their illness (and the absence of any new lesions on serial MRI scans obtained after a mean duration of observation of 3.5-4.5 years), catch-up growth did not occur and volume loss was progressive. Extrapolating this finding to MS, even the first inflammatory insult can have a longterm impact on brain health. As such, a certain proportion of brain atrophy in MS may thus be "pre-ordained" during the subclinical phase or at the time of incident attack, prior to any potential therapeutic intervention. It remains to be seen whether this "committed" brain tissue loss can be halted by even very successful suppression of subsequent inflammation.
What are the key take-home messages from all these studies? As a model, the study of pediatric MS provides a view of the earliest aspects of MS pathobiology. Loss of brain volume in a child or adolescent with MS is highly unlikely to be due to anything other than the MS disease process. Pediatric patients do not have the annual reduction in brain volume that occurs with increasing age in adulthood, nor do they have comorbid diagnoses such as cerebrovascular disease, alcohol, cigarette smoke and other exposures, or other chronic conditions common to adult MS cohorts. 9 While one tends to think of childhood as a period of heightened resilience and greater tissue repair, even if such factors are operative at the focal lesion level (as suggested by magnetization transfer imaging analysis of lesion evolution in pediatric MS patients), 10 such resilience is clearly insufficient.
Arguably, the most seminal message, however, is that MS is a degenerative disease from onset. The finding of Bartels et al., that brain volumes are reduced (without any confound of therapy) 1 , combined with the data showing reduced head size 4 at onset raise several provocative hypothesis (a) that the subclinical onset of MS commences in very early childhood in some patients and negatively impacts maturational brain growth; (b) that the subclinical phase in pediatriconset MS is highly aggressive from biological onset, supported by the very high frequency of clinical relapses, 11 and high-T2 lesion volumes at onset 12 and rapid accrual of new lesions that then occur in the first years post clinical disease expression; 13 and potentially (c) that MS is in fact a neurodegenerative disease, commencing in childhood, that leads to a secondary immune response.
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